Short answer
ADMA BIOLOGICS, INC. (ADMA) filed an 8-K current report with the SEC on February 25, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers). Q4/full-year 2025 earnings release filed February 25, 2026: refer to Exhibit 99.1 for actual financial results.
ADMA BIOLOGICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4/full-year 2025 earnings release filed February 25, 2026: refer to Exhibit 99.1 for actual financial results
- Signed by CEO Adam S. Grossman, indicating standard executive authorization of the disclosure
Item 5.02 · Departure/Election of Directors or Officers
- CFO Brad Tade retiring Feb 25, 2026 post-10-K filing; transitioning to consulting at $41,667/month through July 31, 2026
- Successor Terry Kohler, age 48, promoted from Executive Financial Advisor; prior CFO roles at OptiNose and Verrica Pharmaceuticals
- Kohler compensation: $500K base salary, 45% target bonus, 91,166 stock options + 58,019 RSUs vesting over 4 years
- Severance: 6 months base salary (~$250K) standard termination; 9 months + prorated bonus if Change of Control related
- Orderly transition risk low: Kohler was pre-positioned as Executive Financial Advisor since Dec 2025 specifically for this handoff
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ADMA BIOLOGICS, INC. 8-K filings
Get the next ADMA 8-K as it lands
Follow ADMA for push alerts, or ask the research agent what this filing means.